The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): ##STR00001##
wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): ##STR00001##
wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent.

##STR00001##

wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R.sup.1 is substituted or unsubstituted alkyl etc.; R.sup.2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R.sup.3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R.sup.4 is a hydrogen atom etc.; R.sup.6 is substituted or unsubstituted alkyl etc.

The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent.

##STR00001##

wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R.sup.1 is substituted or unsubstituted alkyl etc.; R.sup.2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R.sup.3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R.sup.4 is a hydrogen atom etc.; R.sup.6 is substituted or unsubstituted alkyl etc.

A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

##STR00001##

The present disclosure provides a method for reducing the aldehyde content in an amine catalyst by treating the amine catalyst with a treating agent selected from a cyclic urea substituted with at least one isocyanate reactive group, a free radical scavenger and a mixture thereof. The treated amine catalyst may then be used in the production of polyurethane materials which exhibit reduced aldehyde emissions.

The present disclosure provides a method for reducing the aldehyde content in an amine catalyst by treating the amine catalyst with a treating agent selected from a cyclic urea substituted with at least one isocyanate reactive group, a free radical scavenger and a mixture thereof. The treated amine catalyst may then be used in the production of polyurethane materials which exhibit reduced aldehyde emissions.

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I):

##STR00001##

wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R.sup.7-R.sup.9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q.sup.1 and Q.sup.2 independently represents a single bond or the like; each of A.sup.1 and A.sup.2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R.sup.1-R.sup.6 independently represents a hydrogen atom or the like.)

##STR00001##